Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527208 · ClinicalTrials.gov registry record · NA
The Meta-SHIFT Study: How Metabolic Shift Shapes Human Immunometabolism - a Fasting Trial
A NA study, sponsored by Cornell University.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT07527208: Recruiting NA study, sponsored by Cornell University.
NCT07527208 is a NA study that is actively recruiting participants, run by Cornell University. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07527208, a NA study, is actively recruiting participants, sponsored by Cornell University.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
During fasting, the body shifts from using carbohydrates to relying more on fat as its main source of energy. This process is known as the 'metabolic shift'. Fat tissue helps supply this energy by breaking down stored fat into fatty acids, which are released into the bloodstream and transported to organs throughout the body. In addition to fatty acids, many other substances in the blood (such as metabolites) change during fasting to help maintain normal body function. Immune cells also circulate in the blood and play an important role in protecting the body against infections and diseases such as cancer. However, it is not yet well understood how the metabolic shift during fasting affects immune cell function. The purpose of this study is to investigate how 24 hours of fasting influences immune cell metabolism and function.
Primary Outcome
Change from baseline PBMC glucose dependence (%) and mitochondrial dependence (%) at 24-hours, as measured by the flow cytometry-based CENCAT method.
Interventions
- OTHER Fasting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT07527208 shows while recruiting
NCT07527208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Fasting is the first listed.
NCT07527208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07527208 about?
NCT07527208 is a clinical study titled "The Meta-SHIFT Study: How Metabolic Shift Shapes Human Immunometabolism - a Fasting Trial". During fasting, the body shifts from using carbohydrates to relying more on fat as its main source of energy. This process is known as the 'metabolic shift'. Fat tissue helps supply this energy by breaking down stored fat into fatty acids, which are released into the bloodstream and transported to o...
What is the current status of trial NCT07527208?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2026-06-01. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07527208?
The interventions under investigation include: Fasting (OTHER).
Who is sponsoring clinical trial NCT07527208?
This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07527208's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI